CPC A61K 31/713 (2013.01) [A61K 9/0019 (2013.01); A61K 38/212 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01)] | 29 Claims |
1. A method for treating a cancer selected from the group consisting of: pancreatic cancer; renal cell carcinoma; colorectal cancer and melanoma, in a subject in need thereof, the method comprising: administering to the subject at least a first compound and a second compound together or separately, wherein the first compound comprises an effective amount of an anti-PD-L1 antibody optionally with at least one pharmaceutically-acceptable carrier, and wherein the second compound is an effective amount of rintatolimod optionally with at least one pharmaceutically-acceptable carrier.
|